JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 45:469, doi:10.1016/j.jacc.2004.11.012
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamond, G. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Diamond, G. A.
Related Collections
Right arrowRelated Article

LETTERS TO THE EDITOR

ADVANCE praise

George A. Diamond, MD, FACC

2408 Wild Oak Drive Los Angeles, CA 90068

(Email: gadiamond{at}pol.net).

Sometimes an artfully crafted quasi-acronym can help distinguish one otherwise indistinguishable clinical advance from another (1–3). The infectiousness of this engaging wOrdPlay is evidenced by a recent report describing the role of Tirofiban for prevention of iscHEmIc complicatioNS among high-risk pAtieNts undergoIng coronary angioplasTY (4)—a distinguished advance indeed!


   References
Top
 References
 

  1. The ADVANCE Investigators Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitusAction in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001;19 Suppl 4:S21-8.
  2. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study J Am Coll Cardiol 2002;39:393-399.[Abstract/Free Full Text]
  3. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial Am Heart J 2003;145:179-186.[CrossRef][ISI][Medline]
  4. Valgimigli M, Percoco GF, Barbieri D, et al. The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (ADVANCE) trial J Am Coll Cardiol 2004;44:14-19.[Abstract/Free Full Text]

Related Article

Reply
Marco Valgimigli and Patrick W. Serruys
J. Am. Coll. Cardiol. 2005 45: 469. [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamond, G. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Diamond, G. A.
Related Collections
Right arrowRelated Article

HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK